About the Authors
- Ricardo J. T. Ribeiro
-
* E-mail: oriebir.r@gmail.com
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal
- Cátia P. D. Monteiro
-
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal
- Andreia S. M. Azevedo
-
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal
- Virgínia F. M. Cunha
-
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal
- Agnihotram V. Ramanakumar
-
Affiliation Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada
- Avelino M. Fraga
-
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Urology Department, D. Pedro V Military Hospital, Porto, Portugal
- Francisco M. Pina
-
Affiliation Urology Department, S. João Hospital, Porto, Portugal
- Carlos M. S. Lopes
-
Affiliation ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal
- Rui M. Medeiros
-
Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal
- Eduardo L. Franco
-
Affiliation Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada
Competing Interests
The authors have read the journal's policy and have the following conflicts: Co-author Rui Medeiros is a PLoS ONE Editorial Board member. The authors received funding from Novartis Oncology Portugal. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RJTR FMP CMSL RMM ELF. Performed the experiments: RJTR CPDM ASMA VFMC AMF FMP. Analyzed the data: RJTR AVR ELF. Contributed reagents/materials/analysis tools: RJTR CMSL RMM. Wrote the paper: RJTR ELF.